Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.

Slides:

Advertisements

Similar presentations

Samsung Medical Center Sungkyunkwan University School of Medicine Hyeon-Cheol Gwon, Joo Yong Hahn, Young Bin Song, Kyung Woo Park, Yang Soo Jang, Hyo-Soo.

Advertisements

수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.

Blood Glucose, Lipids, and Coronary Artery Disease: Emerging Strategies for Multimechanistic Treatment.

DAPT Trial design: Patients undergoing DES/BMS PCI, no ischemic/bleeding complications, and with documented compliance at 1 year, were randomized to receive.

European and US Guidelines

PrEP: A Case-by-Case Approach

EMPHASIS-HF Extended Follow-up

PCSK9 Inhibitors Post-CVOTs

Preventing Thrombotic Complications in ACS: State of the Art

Oral Anticoagulation and Preventing Stent Thrombosis

RESISTANT HYPERTENSION OR POOR PATIENT ADHERENCE? TIPS TO GAIN CONTROL

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

Glenn N. Levine et al. JACC 2016;68:

Acute Heart Failure.

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Heart Failure and Hospital Readmissions

A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.

Achieving Long-Term Protection Post-MI

When Is Adding Aspirin to NOACs Worth the Risk?

Emerging Data on ACS Management From ACC

PAD Patients vs Post-ACS Patients:

A New Era for NOACs:.

Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.

Unmet Needs in the Secondary Prevention in ACS

The Latest Data on Oral Prostacyclin Therapy in PAH

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Medication Nonadherence in Gout

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.

All About PAH:.

Antithrombotics and PAD: A New Paradigm in Practice

What Has Been Tried and What Is True?

Selecting NOACs for High-Risk Patients

Tailoring Antiplatelet Therapy in PCI

Antiplatelet Therapy and Secondary Prevention

Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI

Panelists. Secondary Prevention of Acute Ischemic Stroke: Can We Improve Outcomes?

Terms of Use. Terms of Use.

Talking to Patients About Diabetes Management

Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.

NOACS: Emerging data in ACS/IHD

CV Risk Doesn't End in the Cath Lab

AF and PCI in Practice.

Antithrombotic Protection in CAD and HF

A Better Solution For Cancer Patients With VTE?

Gene Therapy: Past, Present, and Future

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Learning Objectives Metabolic Abnormalities Associated With T2D.

CV Risk Doesn't End in the Cath Lab

Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With and Without Acute Coronary Syndrome Abhishek Sharma, MD,

NIPPON Trial design: Patients undergoing percutaneous coronary intervention were randomized to short-term dual antiplatelet therapy (DAPT) (6 months; n.

ZEUS Trial design: Patients who were deemed uncertain DES candidates due to bleeding, thrombotic, or restenosis risk were randomized to receive either.

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.

Duration of Dual Antiplatelet Therapy

Definition of Elderly. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.

Elevated Admission Plasma Glucose Following ACS

The Challenge of AF and PCI: Practical Strategies to Improve Outcomes

Improving Adherence to Antiplatelet Therapy After an ACS Event

Assessing the Burden of Hyperkalemia

Antiplatelet Therapy Post-ACS: Bridging the CAD Continuum

ITALIC Trial design: Patients with Xience V (everolimus-eluting stent) PCI were randomized in a 1:1 fashion to receive 6 or 24 months of dual antiplatelet.

TL-PAS: DAPT Trial design: Patients undergoing PCI with Taxus Liberté PES, receiving prasugrel, without ischemic/bleeding complications, and compliant.

Assessing the Burden of Hyperkalemia

What's New in Oral Combination Therapy for Type 2 Diabetes?

Top Tips in Evidence-Based Care for HFrEF

PCSK9 Inhibitors and Real-World Evidence

Antithrombotic Therapy in AF Patients Undergoing PCI

Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?

Translating Data From Trial to Practice

Presentation transcript:

Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials

Overview

Case Study

Acute Intervention

Current Medications

Physical Exam/Lab Findings

Subjective

Red Flags for Risk of Nonadherence?

Helpful Tips

Ubiquity of the Nonadherence Problem

Addressing Barriers With the Patient as Partner

DAPT Trial: Stent Thrombosis and MACCE

PEGASUS: HRs and Rates of the Primary Endpoint

Relative Risks for All-Cause Mortality in Good vs Poor Adherence to Major CV Medications

The Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART)

Major Efficacy and Safety Endpoints in PLATO and SWEDEHEART

Case Study: 12-Month Visit

Factors Favoring Longer DAPT

Calculation of a DAPT Score

Multivariable Prediction Model and Derivation of the Score

Effect of Long (12- to 24-Month) vs Short (3- to 6-month) DAPT (ACS Subgroup)

New Paradigms

Clinical Decision Making Vision for the Future

Patient Engagement

Future of Medication Adherence

Concluding Remarks

Abbreviations

Abbreviations (cont)